---
title: Comparison of Tolerability Between Two Allergy Drops
nct_id: NCT01390961
overall_status: UNKNOWN
phase: PHASE4
sponsor: Hom, Milton M., OD, FAAO
study_type: INTERVENTIONAL
primary_condition: Allergic Conjunctivitis
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01390961.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01390961"
ct_last_update_post_date: 2011-07-11
last_seen_at: "2026-05-12T06:17:09.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparison of Tolerability Between Two Allergy Drops

**NCT ID:** [NCT01390961](https://clinicaltrials.gov/study/NCT01390961)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 48
- **Lead Sponsor:** Hom, Milton M., OD, FAAO
- **Collaborators:** Allergan
- **Conditions:** Allergic Conjunctivitis
- **Start Date:** 2011-08
- **Completion Date:** 2012-01
- **CT.gov Last Update:** 2011-07-11

## Brief Summary

Comfort is compared between two allergy drops

## Eligibility

- **Minimum age:** 18 Months
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Between the ages of 18 and over inclusive.
* Males or females
* Patient is in generally good \& stable overall health.
* Patient likely to comply with study guidelines \& study visits.
* Informed consent signed.
* History of allergic conjunctivitis
* Current symptoms of allergic conjunctivitis assessed by the investigator

Exclusion Criteria:

* Corneal refractive surgery or contact lens wear within 6 months of this study.
* Current use of Restasis
* Intra-ocular surgery within 6 months or ocular laser surgery within 6 months.
* Pregnant or lactating women.
* Ocular pathology (includes glaucoma and cataract), which could impact results and/or place patient at risk.
```

## Interventions

- **alacaftadine and naphazoline HCl & pheniramine maleate** (DRUG) — once a day

## Primary Outcomes

- **Tolerability** _(time frame: 8 weeks)_ — Tolerability measured by questionnaire Visual Analog scale 1 to 100

## Locations (1)

- Milton M. Hom, OD, FAAO., Azusa, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.milton m. hom, od, faao.|azusa|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01390961.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01390961*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*